Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06793371 · ClinicalTrials.gov registry record · Phase 2
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
A Phase 2 study of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by Cytokinetics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06793371: Recruiting Phase 2 study of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by Cytokinetics.
NCT06793371 is a Phase 2 study of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) that is actively recruiting participants, run by Cytokinetics. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06793371, a Phase 2 study of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), is actively recruiting participants, sponsored by Cytokinetics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Primary Outcome
Incidence of early drug discontinuation observed during dosing of CK 4021586 in patients with HFpEF
Conditions Studied
Interventions
- DRUG CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
- DRUG Placebo to match CK-4021586
Study Locations (20)
California
- BioSolutions Clinical Research Center - Imperial
- Profound Research LLC - Pasadena
- University of California, San Francisco - Heart and Vascular Center - San Francisco
- FOMAT - Comprehensive Cardiovascular Care - Santa Maria
- Blue Coast Research Center, LLC - Vista
Florida
- New Generation of Medical Research - Hialeah
- Cleveland Clinic Florida - Weston
Alabama
- Eastern Shore Research Institute, LLC - Fairhope
Arizona
- University of Arizona Sarver Heart Center - Tucson
Arkansas
- John L. McClellan Memorial Veterans Hospital - Little Rock
Illinois
- Methodist Medical Center of Illinois - Peoria
Louisiana
- Louisiana Heart Center - Slidell
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT06793371 shows while recruiting
NCT06793371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) appearing as the primary indexed condition, and to 2 interventions - of which CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) is the first listed.
NCT06793371 names 20 study sites across 15 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06793371 about?
NCT06793371 is a clinical study titled "AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF". This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
What is the current status of trial NCT06793371?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-02-06. Estimated completion is 2026-09.
What conditions does trial NCT06793371 study?
This clinical trial studies the following conditions: Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF).
What interventions are being tested in trial NCT06793371?
The interventions under investigation include: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) (DRUG), Placebo to match CK-4021586 (DRUG).
Who is sponsoring clinical trial NCT06793371?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06793371 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06793371's enrollment target sits among peer trials
60 1027th of 2000 higher than 869 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI